Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Diffuse Parenchymal Lung Disease
What factors do you consider when determining whether to perform a biopsy for the diagnosis of organizing pneumonia?
Related Questions
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
What is the duration of steroids that you prescribe for organizing pneumonia?
How do you determine whether to add abatacept or rituximab to the treatment regimen in patients with mild RA-ILD on methotrexate?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
